Uxin Reports Non-GAAP EPS of $0.00 and Revenue of $123.51M; Provides Q4 Guidance and Updates Full-Year Outlook
Q3 Financial Performance: Uxin reported a non-GAAP EPS of $0.00 and revenue of $123.51 million, reflecting a 76.8% year-over-year increase. The adjusted EBITDA showed a loss of RMB5.3 million (US$0.7 million) for the quarter ending September 30, 2025.
Transaction Volume Growth: The company achieved a transaction volume of 15,904 units for Q3 2025, marking a 37.0% increase from the previous quarter and a 125.7% increase from the same period last year. Retail transaction volume also rose significantly to 14,020 units.
Future Outlook: Uxin anticipates retail transaction volume to be between 18,500 and 19,000 units for Q4 2025, with total revenues projected to range from RMB1,150 million to RMB1,180 million. For the full year, retail transaction volume is expected to exceed 50,000 units.
Strategic Partnerships: Uxin has partnered with Yinchuan authorities to establish a used car superstore, indicating a strategic move to enhance its market presence and sales capabilities.
Trade with 70% Backtested Accuracy
Analyst Views on UXIN
About UXIN
About the author

- Joint Venture Formation: Uxin has established Uxin (Jiangyin) Intelligent Remanufacturing Co., Ltd. in partnership with two Jiangsu investment firms, with Uxin Anhui contributing RMB 68 million, representing 68% of the joint venture's registered capital, aimed at supporting Uxin's plan to create a used car superstore in Jiangyin.
- Significant Market Potential: Jiangyin, located in the dynamic Yangtze River Delta, boasts over 30 million residents and more than 12 million vehicles within a 100-kilometer radius, highlighting substantial long-term opportunities in the automotive aftermarket, which Uxin aims to capitalize on through enhanced reconditioning capabilities.
- Industry Standards Enhancement: The joint venture seeks to elevate transparency and brand development in the automotive aftermarket, promoting operational standardization to establish a leading position in the competitive used car market and enhance customer trust.
- Digital Operating Strategy: Uxin plans to leverage its advanced digital operating systems and rigorous service standards to position the Jiangyin superstore as a regional hub for used vehicle distribution and services, further solidifying its market leadership in China's used car industry.
- Joint Venture Formation: Uxin has established Uxin (Jiangyin) Intelligent Remanufacturing Co., Ltd. in partnership with Jiangsu's Huigang Qihang and Chan Fa Ke Chuang, with Uxin Anhui contributing RMB 68 million to a total registered capital of RMB 100 million, marking a strategic move in the used car market.
- Significant Market Opportunity: Located in the heart of the Yangtze River Delta, Jiangyin has over 30 million residents and 12 million vehicles within a 100-kilometer radius, prompting Uxin to enhance automotive aftermarket services to meet growing consumer demand.
- Technological and Service Enhancements: Uxin plans to leverage advanced reconditioning capabilities and integrated digital systems to improve operational efficiency at the Jiangyin superstore, which is expected to enhance customer experience and promote industry transparency and brand development, solidifying its market leadership.
- Strategic Implications: This collaboration represents a deep partnership between Uxin and state-owned enterprises, serving as a crucial initiative to advance the automotive aftermarket industry in Jiangsu Province, indicating Uxin's ongoing innovation and market expansion in the used car sector.
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
- Funding Support: Uxin has entered into binding agreements with NIO Capital and Prestige Shine Group to secure $50 million in funding, which strengthens the company's financial foundation and supports its nationwide superstore expansion.
- Performance Growth: For the quarter ending September 30, 2025, Uxin reported total revenue of 879.3 million Chinese yuan (approximately $123.5 million), marking significant year-over-year growth, with retail vehicle sales exceeding 14,000 units, more than doubling from the previous year, indicating strong market demand.
- Profitability Improvement: Uxin's gross margin increased to 7.5%, while operating and adjusted EBITDA losses narrowed, demonstrating the company's ability to enhance profitability despite rising expansion and marketing costs through higher sales volumes and improved unit economics.
- Future Plans: Founder and CEO Kun Dai stated that the new capital will fund the opening of 4 to 6 new superstores in 2026, further enhancing the company's market competitiveness and financial stability.

- Significant Financing: Uxin Limited has entered into share subscription agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares at $0.00953 each, totaling $50 million, reflecting strong investor confidence in Uxin's future growth.
- Clear Use of Proceeds: The financing is expected to provide sufficient capital to support the launch of four to six new superstores in 2026, which will not only enhance the company's market expansion capabilities but also strengthen its overall financial resilience.
- Strong Investor Background: NIO Capital is committing $20 million while Prestige Shine Group is investing $30 million, indicating Uxin's attractiveness in the industry and its potential for growth.
- Strategic Development Focus: Uxin's Founder and CEO Kun Dai stated that the financing will support the company's long-term strategic goals, aiming to increase market share and brand influence through the establishment of new stores.

- Financing Scale: Uxin has entered into agreements with NIO Capital and Prestige Shine Group to issue 5,246,589,717 Class A ordinary shares, raising a total of $50 million, which reflects strong investor confidence in the company's strategic direction.
- Investment Allocation: NIO Capital will invest $20 million while Prestige Shine Group will contribute $30 million, with proceeds earmarked for launching 4 to 6 new superstores in 2026, thereby enhancing the company's competitive position in the market.
- Financial Resilience: This financing is expected to not only strengthen Uxin's balance sheet but also enhance overall financial resilience, providing sufficient capital support for future expansion plans.
- Market Strategy: Uxin aims to continue executing its established strategy by leveraging new retail experiences and digital empowerment to steadily expand operations in China's used car market, committed to delivering long-term value for shareholders.







